|
| 36942550 | Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. | JAMA | 2023 |
| 37040116 | Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial. | JAMA Netw Open | 2023 |
| 37039790 | Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. | JAMA | 2023 |
| 37227729 | Effect of P2Y12 Inhibitors on Organ Support-Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial. | JAMA Netw Open | 2023 |
| 36875746 | Improving wastewater-based epidemiology performance through streamlined automation. | J Environ Chem Eng | 2023 |
| 36462745 | Platform trials as the way forward in infectious disease' clinical research: the case of coronavirus disease 2019. | Clin Microbiol Infect | 2023 |
| 35040887 | Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial. | JAMA | 2022 |
| 35834252 | Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial. | JAMA Netw Open | 2022 |
| 35468853 | Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer. | Biomark Res | 2022 |
| 35697146 | The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial. | Contemp Clin Trials | 2022 |
| 35598024 | Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. | Alzheimers Res Ther | 2022 |
| 36456573 | Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. | NPJ Breast Cancer | 2022 |
| 36482412 | Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease. | Alzheimers Res Ther | 2022 |
| 36342618 | Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. | Drugs | 2022 |
| 36313200 | Enhanced Ribonucleoprotein Immunoprecipitation (RIP) Technique for the Identification of mRNA Species in Ribonucleoprotein Complexes. | Bio Protoc | 2022 |
| 35993547 | The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials. | Clin Trials | 2022 |
| 36287379 | Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. | Drugs | 2022 |
| 35315874 | Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. | JAMA | 2022 |
| 33297893 | The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods. | Int J Stroke | 2021 |
| 33900369 | Incorporating Adult Evidence Into Pediatric Research and Practice: Bayesian Designs to Expedite Obtaining Child-Specific Evidence. | JAMA | 2021 |
| 33865446 | A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. | Alzheimers Res Ther | 2021 |
| 34611148 | Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. | NPJ Breast Cancer | 2021 |
| 34606578 | Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. | JAMA | 2021 |
| 34741023 | Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial. | Nat Commun | 2021 |
| 34329317 | Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19. | PLoS One | 2021 |
| 34351721 | Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. | N Engl J Med | 2021 |
| 34155411 | A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. | Nat Med | 2021 |
| 33960507 | Bayesian adaptive design for clinical trials in Duchenne muscular dystrophy. | Stat Med | 2021 |
| 34034784 | The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization. | Trials | 2021 |
| 34143979 | Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. | Cancer Cell | 2021 |
| 34257421 | Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study. | Genet Med | 2021 |
| 32484902 | Potential Statistical Issues Between Designers and Regulators in Confirmatory Basket, Umbrella, and Platform Trials. | Clin Pharmacol Ther | 2020 |
| 32031889 | MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. | J Clin Oncol | 2020 |
| 32053137 | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. | JAMA Oncol | 2020 |
| 33362278 | A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates. | PLoS One | 2020 |
| 32994242 | Strategies to Promote ResiliencY (SPRY): a randomised embedded multifactorial adaptative platform (REMAP) clinical trial protocol to study interventions to improve recovery after surgery in high-risk patients. | BMJ Open | 2020 |
| 32790733 | Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. | PLoS One | 2020 |
| 32701140 | Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. | JAMA Oncol | 2020 |
| 32815416 | Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. | Clin Trials | 2020 |
| 32267771 | The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. | Ann Am Thorac Soc | 2020 |
| 30511500 | Bayesian model of disease progression in GNE myopathy. | Stat Med | 2019 |
| 31411020 | Centrifugation-Assisted Immiscible Fluid Filtration for Dual-Bioanalyte Extraction. | Anal Chem | 2019 |
| 31577035 | Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial. | JAMA | 2019 |
| 30926398 | Research Note: Adaptive trials. | J Physiother | 2019 |
| 31070807 | Bayesian hierarchical EMAX model for dose-response in early phase efficacy clinical trials. | Stat Med | 2019 |
| 30983998 | Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis. | Front Pharmacol | 2019 |
| 31104070 | Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. | JAMA | 2019 |
| 29350431 | miFAST: A novel and rapid microRNA target capture method. | Mol Carcinog | 2018 |
| 30069559 | Double-exclusive liquid repellency (double-ELR): an enabling technology for rare phenotype analysis. | Lab Chip | 2018 |
| 30571446 | Letter by Berry et al Regarding Article, "Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials: A Simulation Study". | Stroke | 2018 |